VIVO - Meridian Bioscience Q4 2021 Earnings Preview
Meridian Bioscience (NASDAQ:VIVO) is scheduled to announce Q4 earnings results on Friday, November 12th, before market open. The consensus EPS Estimate is $0.20 (+5.3% Y/Y) and the consensus Revenue Estimate is $68.4M (+6.6% Y/Y). Over the last 2 years, VIVO has beaten EPS estimates 88% of the time and has beaten revenue estimates 63% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward. Revenue estimates have seen 1 upward revision and 0 downward.
For further details see:
Meridian Bioscience Q4 2021 Earnings Preview